Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

@article{Bhatt2019CardiovascularRR,
  title={Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia},
  author={Deepak L. Bhatt and Ph. Gabriel Steg and Michael Miller and Eliot A. Brinton and Terry A. Jacobson and Steven B Ketchum and Ralph T Doyle and Rebecca A Juliano and Lixia Jiao and Craig Granowitz and Jean-Claude Tardif and Christie M. Ballantyne},
  journal={The New England Journal of Medicine},
  year={2019},
  volume={380},
  pages={11–22}
}
BACKGROUND Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS We performed a multicenter, randomized, double‐blind, placebo‐controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a… 

Figures and Tables from this paper

Cardiovascular risk reduction with icosapent ethyl.

Icosapent ethyl was rigorously shown to decrease residual risk for cardiovascular events, though the benefits seen were likely because of mechanisms beyond mere triglyceride lowering.

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk

Since IPE significantly decreases total ischemic events in the aforementioned patient population, it would be intriguing to know whether IPE alone added an advantage to lifestyle modification in the low-risk population, who has serum triglyceride between 150 mg/dl and 499  mg/dl.

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Olezarsen significantly reduced apoC-III, triglycerides, and atherogenic lipoproteins in patients with moderate hypertriglyceridaemia and at high risk for or with established cardiovascular disease.

The role of icosapent ethyl in cardiovascular risk reduction

This review summarizes the results from outcome trials conducted with omega-3 fatty acids, differentiating between those with combinations of EPA/DHA and those with pure EPA, as well as imaging and preclinical data that help explain the different cardiovascular efficacy observed.

Hypertriglyceridaemia — REDUCE-IT with icosapent ethyl

The clinical benefits exceeded what I would expect from the 20% reduction in triglyceride levels, and Robert Hegele suggests that potential pleiotropic effects of icosapent ethyl include an anti-inflammatory effect, given that the level of C-reactive protein measured by high-sensitivity assay was lower with icOSapent Ethyl than with placebo.

Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides

Evidence and recommendations related to triglyceride-lowering therapy in the primary and secondary preventive settings are summarized and expert opinion Icosapent ethyl is a stable, highly purified ethyl ester of eicosapentaenoic acid that safely and effectively reduces cardiovascular events in the contemporary setting.

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap

High-dose icosapent ethyl intervention confers substantial cardiovascular benefit in high-risk patients with moderate hypertriglyceridaemia on statin therapy, and a recent intervention trial evaluating a high dose of eicosapentaenoic-acid showed clear benefit.

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories.
...

References

SHOWING 1-10 OF 47 REFERENCES

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events.

Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol

CVD risk in high-risk statin-treated patients with atherosclerotic CVD was associated with high TG levels, and the primary outcomes were a composite of nonf fatal myocardial infarction, nonfatal stroke, unstable angina, coronary revascularization, and all-cause mortality.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.

Relationships between plasma fatty acid composition and coronary artery disease.

The risk of coronary artery disease is influenced by variations in plasma fatty acid composition among n-3 polyunsaturated fatty acids, and EPA and DHA exhibited differences in the correlation with the risk of major coronary events.

Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus

Among patients with diabetes without evidence of cardiovascular disease, there was no significant difference in the risk of serious vascular events between those who were assigned to receive n‐3 fatty acid supplementation and those who are assigned to receiving placebo.